Bio Business

» biobusiness, pharma and nonprofit

Most Recent

image: Accessing Drugs for Medical Aid-in-Dying

Accessing Drugs for Medical Aid-in-Dying

By | August 17, 2017

A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

0 Comments

image: Learning from Iceland’s Model for Genetic Research

Learning from Iceland’s Model for Genetic Research

By | June 1, 2017

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

1 Comment

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Cannabis Biotech

Cannabis Biotech

By | December 1, 2014

As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

2 Comments

image: Incubator Boom

Incubator Boom

By | March 1, 2014

From San Francisco to St. Louis, biotech incubators are proliferating across North America. Can they deliver on their promise of fueling the economy?  

2 Comments

image: Biology Hacklabs

Biology Hacklabs

By | March 1, 2013

Fueled by donations, sweat, and occasional dumpster diving, community laboratories for DIY biologists are cropping up around the country.

2 Comments

image: Treating Fat with Fat

Treating Fat with Fat

By | May 1, 2012

Is brown fat ready for therapeutic prime time?

22 Comments

image: Braving the IPO Drought

Braving the IPO Drought

By | March 1, 2012

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

0 Comments

image: Make Mine Rare

Make Mine Rare

By | August 1, 2011

With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.

6 Comments

Popular Now

  1. GM Mosquitoes Closer to Release in U.S.
  2. Effects of Neanderthal DNA on Modern Humans
  3. Flux and Uncertainty in the CRISPR Patent Landscape
  4. Do Pathogens Gain Virulence as Hosts Become More Resistant?
RayBiotech